SOURCE: BDI Pharma, Inc.

BDI Pharma, Inc.

March 04, 2010 11:19 ET

Biotech Distributor BDI Pharma to Continue Accepting Flu Pre Books as New H1N1 Recommendation for Seasonal Vaccine Emerges

COLUMBIA, SC--(Marketwire - March 4, 2010) -  BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, will continue accepting pre book orders for the 2010 - 2011 flu season, as recent recommendations provided by the FDA's Vaccines and Related Biological Products Advisory Committee suggest that manufacturers include the H1N1 strain in the upcoming seasonal flu vaccine. Due to these recommendations, BDI anticipates an uptake in pre book orders.

"Due to last year's H1N1 pandemic, this past flu season proved to be one of the industry's most challenging in recent history. As manufacturers shifted their attention to the production of H1N1, the seasonal flu vaccine became increasingly scarce" said Jennifer Jacobson, VP of Corporate Programs for BDI. "The importance of pre booking became fundamentally clear when healthcare providers that booked with us early received their orders in full, thus avoiding the challenges faced by others who waited until the season began."

BDI Pharma accepts pre books for seasonal flu vaccine over the phone, via fax or through their dedicated flu program website, www.securiflu.com. Providers may call customer service at 1-800-948-9834, fax their completed pre book forms to 803-781-3349 or sign in to the easy-to-use SecuriFLU website and place their orders electronically.

To view the article regarding the FDA's new recommendations, visit http://www.flu.gov/news/blogs/blog20100222.html

About BDI Pharma, Inc.

Serving the healthcare community since 1995, BDI Pharma, Inc. has built an outstanding reputation as an industry source for products and service. BDI Pharma's market focus is evident in its commitment to specialty biotherapeutics, chemotherapies, vaccines and plasma protein therapies, including Albumin, intravenous immune globulin (IVIG or IGIV), coagulation factors VIII, IX, and VIIa, hyper-immunes, and injectables. As a manufacturer recognized Authorized Distributor of Record, BDI Pharma, Inc. services the entire country and is fully accredited and insured, fulfilling the licensing requirements in all 50 states.

In an arena where access to pertinent clinical data and updated information on market availability is paramount to patient care, BDI Pharma, Inc. defines its customer-centric approach to serving the nation's healthcare community through innovative inventory management programs, unparalleled customer service, extensive product knowledge, unique promotional services, emergency availability and urgent need delivery. The company serves as a source for reference material and market data, offering healthcare providers the latest information on products, supply and other industry events. BDI Pharma, Inc.'s educational literature and Web site -- www.bdipharma.com -- serve as open-access resources, contributing to the promotion of the biopharmaceutical industry and the education of both the healthcare community and general populace.

Contact Information

  • Contact:
    Brad Davis
    Director of Marketing
    Email Contact
    (800)948-9834